Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron with or without tamsulosin or Yinhuamiyanling for ureteral stent-related symptoms
ChiCTR2000031840Phase 4Not yet recruiting
- Sponsor
- Qingdao Hospital of Traditional Chinese Medicine
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mirabegron and tamsulosin in ureteral stent-related symptoms (USRS) (4 arms), sponsored by Qingdao Hospital of Traditional Chinese Medicine. Primary endpoint: Ureteral stent symptom questionnaire. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
mirabegrontamsulosin
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on ChiCTR2000031840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031840.